Alcon stock faces tighter 2026 outlook after mixed third-quarter results

Alcon reported stronger earnings but softer-than-expected sales for the third quarter ended September 30, 2026, and narrowed its full-year profitability outlook. The company's November 10 release put quarterly sales at 2.717 billion US dollars, up 5% from the year-earlier period on both a reported and constant-currency basis.

Core diluted earnings per share rose 15% to 0.91 US dollars, while reported diluted earnings per share increased 13% to 0.54 US dollars. Net income advanced to 260 million US dollars from 237 million US dollars. Alcon said core operating income increased 13% to 591 million US dollars, lifting the core operating margin to 21.8% from 20.2% a year earlier.

Sales Growth Meets Competitive Pressure

The quarterly performance was uneven across the business. Surgical sales rose 4% to 1.480 billion US dollars, supported by 6% growth in consumables and an 11% increase in equipment and other products. Implantables sales fell 2% to 422 million US dollars as competitive pressure in the United States weighed on intraocular lens demand, although PanOptix Pro and international markets provided some support.

Vision Care sales increased 6% to 1.237 billion US dollars. Contact lenses grew 4%, or 5% excluding currency effects, with premium products and U.S. price increases partly offset by declines in legacy products. Ocular health sales climbed 8% to 500 million US dollars, led by the dry-eye portfolio including Tryptyr and Systane.

For the first nine months, Alcon generated 8.184 billion US dollars in sales, up 7% on a reported basis and 6% in constant currency. Core diluted earnings per share reached 2.60 US dollars, an increase of 14% on a reported basis. Reported nine-month earnings were affected by a 402 million US dollar pretax, non-cash charge connected with the discontinuation of the PowerVision programs, alongside efficiency costs and other items.

Guidance Range Becomes More Precise

Alcon now expects 2026 sales growth of approximately 6% in constant currency, compared with the previous range of 5% to 7%. The company also narrowed its expected core operating-margin expansion to 100 to 150 basis points from 90 to 190 basis points. Core diluted earnings per share growth is now forecast at 12% to 14%, versus the former range of 12% to 15%.

Management's assumptions include eye-care market growth of approximately 3%, exchange rates prevailing at the end of October and a full-year tariff impact of approximately 40 million US dollars after mitigating actions and refunds. Alcon also expanded its efficiency program in November, increasing estimated total costs to approximately 230 million US dollars and expected run-rate savings to approximately 130 million US dollars.

Chief Executive David J. Endicott said the company remained on track for its 2026 objectives despite competitive pressure, pointing to momentum in newer products and the strength of the pipeline. The company also highlighted its Neurotech acquisition, which expands its retina portfolio with the ENCELTO treatment.

Investors Focus On The Lower Range

Morningstar, citing Dow Jones Newswires, reported that Zurich-listed Alcon shares fell 7.7% in European morning trading on November 11 after the sales growth missed Visible Alpha expectations and the outlook was tightened. The report said analysts at RBC Capital Markets saw less scope for positive surprises, while Vontobel highlighted the U.S. implantables pressure.

Alcon stock traded at 65.81 euros on Lang & Schwarz at 10:18 CET on Thursday, November 12, 2026.

For investors, the narrowed range reduces uncertainty around the company's 2026 delivery but also sets a higher burden for further upside surprises. The next focus is execution in implantables and continued adoption of newer surgical, contact-lens and ocular-health products. Broader Swiss equity-market developments can be followed in the SMI market overview.

More news and analyses on Alcon stock.